A-Alpha Bio starts AI antibody data consortium with GSK, Boltz

David Younger, A-Alpha Bio CEO July 21, 2026 07:00 AM EDT R&DAI Ex­clu­sive: A David Bak­er spin­out launch­es AI an­ti­body da­ta con­sor­tium with GSK, Boltz and oth­ers Andrew Dunn Senior Biopharma Correspondent Bio­phar­ma’s AI en­gines need more da­ta. And David Younger thinks there’s a great busi­ness to sell those da­ta to them. Younger’s start­up, A-Al­pha Bio, has … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER